Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
tumor subtype
|
| gptkbp:associatedWith |
RAS/MAPK pathway activation
|
| gptkbp:clinicalTrialPhase |
NCT02383927
NCT03719690 |
| gptkbp:foundIn |
gptkb:cancer
gptkb:head_and_neck_squamous_cell_carcinoma bladder cancer |
| gptkbp:frequency |
rare
|
| gptkbp:hasBiomarker |
HRAS mutation
|
| gptkbp:hasOncogenicDriver |
gptkb:HRAS
|
| gptkbp:hasPotentialTherapy |
gptkb:tipifarnib
gptkb:MEK_inhibitors farnesyltransferase inhibitors ERK inhibitors salirasib |
| gptkbp:hasResistanceMechanism |
secondary RAS mutations
upregulation of alternative pathways |
| https://www.w3.org/2000/01/rdf-schema#label |
HRAS-mutant tumors
|
| gptkbp:mutationAssociatedWith |
gptkb:HRAS
|
| gptkbp:prognosis |
variable
|
| gptkbp:bfsParent |
gptkb:tipifarnib
|
| gptkbp:bfsLayer |
7
|